

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713618290>

Synthesis and Anti-HIV Activity of New 6-Thioarylpyrimidines and Related Compounds

Iman A. Al-Masoudi^a; Yaseen A. Al-Soud^b; Najim A. Al-Masoudi^c; Saman H. Noori^d; Thilo Schuppler^e

^a College of Veterinary, University of Basrah, Basrah, Iraq ^b Department of Chemistry, College of Science, University of Al al-Bayt, Al-Mafraq, Jordan ^c Fachbereich Chemie, Universität Konstanz, Postfach 5560, Konstanz, Germany ^d Department of Biochemistry, College of Medicine, University of Sulaimani, Sulaimani, Iraq

To cite this Article Al-Masoudi, Iman A. , Al-Soud, Yaseen A. , Al-Masoudi, Najim A. , Noori, Saman H. and Schuppler, Thilo(2008) 'Synthesis and Anti-HIV Activity of New 6-Thioarylpyrimidines and Related Compounds', *Phosphorus, Sulfur, and Silicon and the Related Elements*, 183: 7, 1571 — 1583

To link to this Article: DOI: 10.1080/10426500701693453

URL: <http://dx.doi.org/10.1080/10426500701693453>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Synthesis and Anti-HIV Activity of New 6-Thioarylpyrimidines and Related Compounds

Iman A. Al-Masoudi,¹ Yaseen A. Al-Soud,²
Najim A. Al-Masoudi,³ Saman H. Noori,⁴
and Thilo Schuppler³

¹College of Veterinary, University of Basrah, Basrah, Iraq

²Department of Chemistry, College of Science, University of Al al-Bayt, Al-Mafraq, Jordan

³Fachbereich Chemie, Universität Konstanz, Postfach 5560, D-78457 Konstanz, Germany

⁴Department of Biochemistry, College of Medicine, University of Sulaimani, Sulaimani, Iraq

A series of new 5-nitro- and 5-amino-6-arylsulfanyl-1-propyl-1H-pyrimidin-2,4-diones (4–9) were synthesized with the aim to develop new non-nucleoside reverse transcriptase inhibitors (NNRTIs). Similarly, 6-arylsulfanyl-1,3-dimethyl-5-nitro-1H-pyrimidin-2,4-diones (12–15) were prepared from 10. A new 2-amino-2-phenyl-7-phenylsulfanyl-imidazo[1,2-a]pyrimidin-5-one (18) has been synthesized from reaction of 17 with α -bromoacetophenone in the presence of NaH. The newly synthesized compounds were evaluated for their anti HIV-1 and HIV-2 activity in MT-4 cells.

Keywords 6-arylsulphanyl-pyrimidones; anti-HIV activity; imidazo[1,2-a]pyrimidin-5-one; non-nucleoside reverse transcriptase inhibitors (NNRTIs)

INTRODUCTION


To the chemotherapist, the revelation of a new chemical class with potent activity against the HIV-1 reverse transcriptase, the key enzyme in the HIV replication, and the target for developing anti-HIV drugs, is always exciting; meanwhile, the attempts are continuing to discover drugs that can interfere with a stage in the viral replicative cycle without damaging the normal processes of the host cell.

Two types of reverse transcriptase inhibitors have been developed,^{1–3} nucleoside reverse transcriptase inhibitors (NRTIs)

Received 31 July 2007; accepted 27 August 2007.

Address correspondence to Najim A. Al-Masoudi, P.O. Box 10 05 52, D-78405 Konstanz, Germany. E-mail: Najim.Al-Masoudi@gmx.de

and non-nucleoside reverse transcriptase inhibitors (NNRTIs). Three NNRTIs, nevirapine,⁴ delaviridine,^{5,6} and efavirenz⁷ have been approved by the FDA for the treatment of HIV infection. However, significant resistance has been developed against the current NNRTIs and therefore there is an urgent need to develop new anti-HIV agents that are effective against these resistant mutants.^{8,9} Several potent 6-alkylsulfanyl or sulphonyl-5-nitrouracil family attracts significant attention due to their chemotherapeutic importance against HIV. Benhida et al.¹⁰ have reported the synthesis of various derivatives of 1-ethoxymethyl-6-alkylsulphanyl and 6-arylsulphonyl-1*H*-pyrimidine-2,4-diones and the 5-nitro analogues with potent anti-HIV-1 activities in CEM/SS cells. On the other hand, Yousif and Yamamoto¹¹ have prepared similar 6-alkyl or arylsulfanyl analogues with different substituents at N-1. However, 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (**1**) (HEPT) has been synthesized by Miyasaka et al.¹² and Al-Soud and Al-Masoudi¹³ with high anti-HIV inhibitory activity as an interesting example in this series. In our recent work, we reported new 5-nitro-1-propyl- or 1,3-dimethyl-5-nitro-1*H*-pyrimidin-2,4-diones having 6-arylsulfanyl groups and their amino analogues as HIV-1 and HIV-2 replication inhibitors.




RESULTS AND DISCUSSION

Chemistry

Various 5-alkyl- and 5-arylsulfanyl derivatives of 4-nitroimidazole derivatives as well as the 5-substituted-piperazine analogues have been prepared recently in our laboratory^{14–19} via nucleophilic displacements of the bromine group activated by an adjacent nitro group. Several alternative potential heterocyclic bases, other than imidazole derivatives, such as pyrimidine bases substituted by various potential groups^{20–28} were prepared from their chloro analogue²⁰ via nucleophilic

displacements. Analogously, our efforts are focused on the preparation of new pyrimidines carrying arylsulfanyl groups, which might lead to biological active candidates. 6-Chloro-5-nitro-1-propyl-1*H*-pyrimidin-2,4-dione (**3**), prepared from nitration of **2**,¹¹ has been selected for the synthesis of our targets by treatment with different arylsulfanyl nucleophiles, such as sodium phenylthiolate, 4-pyridinethiol and 4-(*N*-oxidepyridine)thiol in the presence potassium carbonate in hot DMF or ethanol to give, after purification, **4–6** in 69, 55, and 51% yield, respectively. Reduction of **4** with H₂/Pd-C in methanol for 5 h afforded, after purification, **7** (79%).

Treatment of **7** with formaldehyde in acetonitrile followed by reduction of the inseparable product with sodium cyanoborohydride (NaBH₃CN) under reflux for 3 h afforded, after chromatographic purification, **8** (74%). On the other hand, refluxing of **7** with 3,4-dimethoxyphenylaldehyde in ethanol gave **9** (77%) (Scheme 1).




SCHEME 1 Reagents and conditions: (i) HNO₃/H₂SO₄, 5°C; (ii) ArSNa or ArSH, DMF (120°C) or EtOH (reflux); (iii) H₂/Pd-C, MeOH, 5 h; (iv) HCOH (10 equiv.), NaBH₃CN (3 equiv.), MeCN, reflux, 3 h.

The structures of the newly synthesized compounds **4–9** were assigned by the ¹H, ¹³C NMR and mass spectra. The ¹H NMR spectra of **4–9** showed rather similar patterns for the N-1 propyl protons. Thus, the multiplets in the region δ 3.67–3.38 ppm and δ 1.49–1.42 ppm were

attributed to the methylene protons of C-1' and C-2', respectively; meanwhile the triplets resonated in the region δ 0.83–0.81 ppm ($J \sim 7.0$ Hz) were attributed to CH₃ of N-1-propyl group. The resonances of the aryl moiety of **4**, **7–9** appeared as multiplets in the region δ 7.63–7.22 ppm, meanwhile the same moiety of **4** and **5** were appeared as doublets in the region δ 8.76–7.30 ppm ($J=7.6$ Hz). In the ¹³C NMR spectra of **4–9**, C-2 and C-4 of the pyrimidine ring resonated at the region δ 166.8–157.0 ppm, and δ 151.1–148.1 ppm, respectively. C-6 of **4–6** resonated at δ 159.1, 156.9, and 158.2 ppm, respectively, while it appeared at δ 127.2 and 125.8 ppm, respectively, for **7** and **8**. C-5 bearing nitro group of **4–8** resonated at δ 116.0–106.9 ppm, while appeared at δ 90.8 ppm for **9**.

Next, other models of 6-arylsulfanyl pyrimidine derivatives bearing N-1 and N-3 substituted methyl groups were prepared. Thus, treatment of **11**,^{29,30} prepared from nitration of **10**, with sodium phenylthiolate, 4-pyridinethiol, 4-(*N*-oxidepyridine)thiol, and 4-chlorophenylthiolate in the presence of triethylamine in hot ethanol gave, after purification, **12–15** in 69, 52, 61, and 53% yield, respectively (Scheme 2).




SCHEME 2

The assignment of protons and carbons of the pyrimidine ring, and the substituents were deduced in comparison to compounds **4–6** and the previously reported data on 6-arylsulfanyl pyrimidines.^{11,12}

In the ¹H NMR spectra of **12–15**, the N-1 and N-3 methyl groups were resonated at the region δ 3.11–3.00 ppm. The ¹³C NMR spectra of **12–15** were almost similar to those of the analogues **4–6**.

Gross et al.³¹ have described the identification of pyrrolo-pyrimidones, 2-arylimidazol[1,2-*a*]-pyrimidone series and imidazolo [1,2-*a*]-pyrimidin-5-ones as potent GnRH receptor antagonists by reaction of 2-amino-pyrimidone derivatives with α -bromoacetophenone. We have selected 2-amino-6-chloro-5-nitro-pyrimidin-4-one (**16**) as a key intermediate in synthesis of new 5-nitro-6-phenylsulfanyl-imidazo[1,2-*a*]-pyrimidin-4-one (**18**) in attempt to evaluate its anti-HIV activity. Thus, treatment **16** with PhSNa in DMF at 120°C, afforded **17** (65%). Compound **17** was converted into 2-amino-2-phenyl-7-phenylsulfanyl-imidazo[1,2-*a*]pyrimidin-5-one (**18**) (51%) by treatment with α -bromoacetophenone in the presence of NaH in DMF (Scheme 3).



SCHEME 3 Reagents and conditions. (i) PhSNa, DMF, 120°C, 3 h; (ii) α -bromoacetophenone, DMF, NaH, 23°C, 5 h, followed by addition of NH₄OH at 23°C.

The structures of **17** and **18** were confirmed by the ¹H-, ¹³C NMR, and mass spectra. In the ¹³C NMR spectrum of **18**, C-5 and C-7 appeared at the higher field δ 188.2 ppm and δ 173.2 ppm, respectively, in comparison to the same atoms of the adduct **17** (C-4: δ 163.6 ppm and C-6: 142.8 ppm). The bridge carbon atom C-9 of **18** resonated at the lower field (δ 124.3 ppm) compared to C-2 of the adduct **17** (δ 150.2 ppm). The structure of **18** was further confirmed by the homo- and heteronuclear NMR study. The gradient selected HMBC³² spectrum allowed ²*J*_{C,H} coupling the assignment of C-2 at δ _C 139.8 ppm by correlation with H-3 at δ _H 7.15 ppm, while it showed ³*J*_{C,H} between H-3 and C-5 and C-9 at δ _C 188.2 ppm and δ _C 144.6 ppm, respectively. Its mass spectra exhibited the correct molecular ion [M+H]⁺ (426).

In-vitro Anti-HIV Assay

Various compounds have been reported to inhibit the replication of human immunodeficiency virus type 1 (HIV-1) in vitro.³³ Among these, compound is HEPT 1, a potent and selective inhibitor of HIV-1 in

TABLE I In Vitro Anti-HIV-1^a and HIV-2^b of Some New 6-Arylthiopyrimidines

Compound	Virus strain	EC ₅₀ (μg/mL) ^c	CC ₅₀ (μg/mL) ^d	SI ^e
3	III _B	>62.40	≥ 62.40	≤ 1
	ROD	>62.40	≥ 62.40	≤ 1
4	III _B	>72.90	>72.90	≤ 1
	ROD	>72.90	>72.90	≤ 1
5	III _B	>76.63	76.63	<1
	ROD	>76.63	76.63	<1
6	III _B	>0.313	0.313	<1
	ROD	>0.313	0.313	<1
7	III _B	>44.30	≥ 44.30	<1
	ROD	>44.30	≥ 44.30	<1
12	III _B	>81.20	≥ 81.20	≤ 1
	ROD	>81.20	≥ 81.20	≤ 1
13	III _B	>11.60	11.60 ± 1.07	<1
	ROD	2.54	11.60 ± 1.07	5
14	III _B	>0.275	0.275 ± 0.233	<1
	ROD	>0.275	0.275 ± 0.233	<1
17	III _B	>88.07	88.07 ± 39.77	<1
	ROD	>88.07	88.07 ± 39.77	<1
18	III _B ROD	>2.56 >2.56	2.56 2.56	<1
Efavirenz	III _B	0.003	40	13333
Capravirine	III _B	0.0014	11	7857

^aAnti-HIV-1 activity measured with strain III_B.
^bAnti-HIV-2 activity measured with strain ROD.
^cCompound concentration required to achieve 50% protection of MT-4 cells from the HIV-1- and 2-induced cytopathogenic effect.
^dCompound concentration that reduces the viability of mock-infected MT-4 cells by 50%.
^eSI: Selectivity index (CC₅₀/EC₅₀).

various T4 cells cultures, including peripheral blood lymphocyte (PBL) cells.³⁴

In this study, we explored new analogues resemble in their structure to HEPT. The new synthesized analogues **3-7,12-14, 17**, and **18** were evaluated for their in vitro anti-HIV-1 activity by using the IIIB strain for HIV-1 and the ROD strain for the HIV-2, and monitored by the inhibition of the virus-induced cytopathic effect in the human T-lymphocyte (MT-4) cells. The results are summarized in Table I, in which the data for efavirenz⁷ and capravirine³⁵ were included for comparison purposes. Compound **6, 13** and **14** were found to be the only compounds from the series inhibiting HIV-1 replication in cell culture. Compounds **6** and **14** showed anti-HIV-1 and HIV-2 with EC₅₀ > 0.313 μg/mL and >0.275 μg/mL, respectively, but with no selectivity can be witnessed (SI < 1).

Compound **13** showed higher value of EC_{50} against HIV-2 ($2.54 \mu\text{g/ml}$), with $CC_{50} = 11.60 \mu\text{g/ml}$, resulting with selectivity value (SI) of 5.

CONCLUSIONS

Compound **6** and **14** are equipotent against HIV-1 and HIV-2 replication in vitro, and therefore, it is not likely an NNRTI, meanwhile compound **13** showed some selectivity (SI = 5) against HIV-2 ($EC_{50} = 2.54 \mu\text{g/mL}$), confirming the typical first generation NNRTI mode of action of this compound. The structure-activity relationships (SARs) of 6-arylpyrimidine derivatives have suggested the importance of thioaryl group on the pyrimidine ring, especially the pyridine-*N*-oxide residue, for potent inhibitory activity against RT, then lead to the discovery of more potent and selective analogues that will allow the elucidation of their molecular mode of action.

EXPERIMENTAL

General Procedure

Melting points were measured on a Büchi melting point apparatus B-545 (BÜCHI Labortechnik AG, Switzerland) and are uncorrected. Microanalytical data were obtained with a Vario, Elementar apparatus (Shimadzu, Japan). NMR spectra were recorded on 300 and 600 MHz (^1H) and at 150.91 MHz (^{13}C) spectrometers (Bruker, Germany) with TMS as internal standard and on δ scale in ppm. Heteronuclear assignments were verified by ^1H - ^{13}C HMBC experiment. Mass spectra were recorded on 70 eV EI and FAB MAT 8200 spectrometers (Finnigan MAT, USA), using 3-nitrobenzyl alcohol (NBOH) or glycerol as matrix. Some molecular ions were detected by doping the sample with Na^+ ion.

6-Chloro-5-nitro-1-propyl-1H-pyrimidin-2,4-dione (**3**)¹¹

6-Chloro-1-propyluracil (**2**) (1.0 g, 5.29 mmol) was added in a portion to a stirred concentration of H_2SO_4 (3.0 mL), kept below 15°C by cooling in ice. Fuming HNO_3 (3.0 mL) was added slowly—being maintained at 0 – 5°C , and the solution was then poured onto ice (40 g) with stirring. The product was at once extracted with chloroform ($2 \times 30 \text{ mL}$) and the combined extract was dried (Na_2SO_4), filtered and quickly evaporated to give **3** (78%) as a yellow solid; m.p. 90 – 92°C . ^1H NMR ($\text{DMSO}-d_6$): δ 10.06 (s, 1H, NH); 3.59 (m, 2H, CH_2 -1'); 1.45 (m, 2H, CH_2 -2'); 0.80 (t, 3H, $J = 7.5 \text{ Hz}$, CH_3). ^{13}C NMR ($\text{DMSO}-d_6$): δ 157.6 (C-4); 150.6 (C-2); 150.1 (C-6); 123.9 (C-5), 42.0 (C-1'); 21.0 (C-2'); 11.1 (C-3'). Anal. calcd.

for $C_7H_8ClN_3O_4$ (233.61): C, 35.99; H, 3.45; N, 17.99. Found: C, 35.78; H, 3.32; N, 17.79.

5-Nitro-6-arylsulfanyl-1-propyl-1*H*-pyrimidin-2,4-diones (4–9, 11)—General Procedure

A solution of **3** (4.28 mmol) in DMF (20 mL) or ethanol (20 mL) and arylmercaptan (6.42 mmol) was heated at 120°C (DMF) or under reflux (ethanol) for 8–10 h. After cooling, the solution was evaporated to dryness and the residue was recrystallized from ethanol or ethanol/methanol to give the desired product.

5-Nitro-6-phenylsulfanyl-1-propyl-1*H*-pyrimidin-2,4-dione (4)

From sodium phenylthiolate (0.85 g). Yield: 1.36 g (69%), m.p. 109–111°C. 1H NMR (DMSO- d_6): δ 7.59 (m, 2H, Ar-H); 7.31 (m, 3H, Ar-H); 3.61 (m, 2H, CH_2 -1'); 1.45 (m, 2H, CH_2 -2'); 0.81 (t, 3H, J = 7.1 Hz, CH_3). ^{13}C NMR (DMSO- d_6): δ 162.1 (C-4); 159.1 (C-6); 148.1 (C-2); 129.5, 128.6, 128.4, 126.1 (Ar-C); 113.8 (C-5), 50.8 (C-1'); 21.8 (C-2'); 11.8 (C-3'). Anal. Calcd. for $C_{13}H_{13}N_3O_4S$ (307.33): C, 50.81; H, 4.26; N, 13.67. Found: C, 50.60; H, 4.13; N, 4.02. MS: m/z (FAB) 308 ($M+H$)⁺.

5-Nitro-1-propyl-6-(pyridin-4-ylsulfanyl)-1*H*-pyrimidin-2,4-dione (5)

From 4-pyridinethiol (0.72 g). Yield: 55%, m.p. 311–312°C. 1H NMR (DMSO- d_6): δ 9.89 (s, 1H, NH); 8.76 (d, 2H, J = 7.6 Hz, Ar-H); 7.55 (d, 2H, J = 7.6 Hz, Ar-H); 3.45 (m, 2H, CH_2 -1'); 1.49 (m, 2H, CH_2 -2'); 0.83 (t, 3H, J = 7.0 Hz, CH_3). ^{13}C NMR (DMSO- d_6): δ 163.2 (C-4); 156.9 (C-6); 150.3 (C-2); 129.5, 128.6, 128.4, 126.1 (Ar-C); 116.0 (C-5), 45.2 (C-1'); 21.1 (C-2'); 11.1 (C-3'). Anal. calcd. for $C_{12}H_{12}N_4O_4S$ (308.32): C, 46.74; H, 3.92; N, 18.17. Found: C, 46.52; H, 3.79; N, 17.88. MS: m/z (FAB) 309 ($M+H$)⁺.

5-Nitro-1-propyl-6-(pyridin-*N*-oxide-4-ylsulfanyl)-1*H*-pyrimidin-2,4-dione (6)

From 4-(*N*-oxidepyridine)thiol (0.81 g). Yield: 1.06 g (51%), m.p. 95–98 dec.°C. 1H NMR (DMSO- d_6): δ 8.00 (d, 2H, J = 7.6 Hz, Ar-H); 7.30 (d, 2H, J = 7.6 Hz, Ar-H); 3.58 (m, 2H, CH_2 -1'); 1.43 (m, 2H, CH_2 -2'); 0.81 (t, 3H, J = 7.0 Hz, CH_3). ^{13}C NMR (DMSO- d_6): δ 166.8 (C-4); 158.2 (C-6); 150.2 (C-2); 138.2 (Ar-Cc,e); 131.3 (Ar-Cb,f); 113.5 (C-5); 48.5 (C-1'); 21.1 (C-2'); 11.1 (C-3'). Anal. calcd. for $C_{12}H_{12}N_4O_5S$ (324.31): C, 44.44; H, 3.73; N, 17.28. Found: C, 44.22; H, 3.68; N, 17.05. MS: m/z (FAB) 325 ($M+H$)⁺.

5-Amino-6-phenylsulfanyl-1-propyl-1H-pyrimidin-2,4-dione (7)

A solution of **3** (0.70 g, 2.27 mmol) in methanol (20 mL) and Pd/C (150 mg) was stirred under H₂ for 5 h. The solid was filtered and the solution was evaporated to dryness. The residue was recrystallized from ethanol to give **7** (0.50 g 79%), m.p. 143–146°C. ¹H NMR (DMSO-*d*₆): δ 9.95 (s, 1H, NH); 8.83 (br s., 2H, NH₂); 7.41–7.32 (m, 5H, Ar-H); 3.59 (m, 2H, CH₂-1'); 1.45 (m, 2H, CH₂-2'); 0.81 (t, 3H, *J* = 7.1 Hz, CH₃). ¹³C NMR (DMSO-*d*₆): δ 163.5 (C-4); 150.2 (C-6); 133.8; 127.8, 125.0, 121.0 (Ar-C, C-6); 106.9 (C-5); 48.5 (C-1'); 21.1 (C-2'); 11.2 (C-3'). Anal. calc. for C₁₃H₁₅N₄O₂S (277.34): C, 56.30; H, 5.45; N, 15.15. Found: C, 50.02; H, 5.37; N, 14.89. MS: *m/z* (FAB) 300 (M+Na)⁺.

5-(Dimethylamino)-6-phenylsulfanyl-1-propyl-1H-pyrimidin-2,4-dione (8)

To a suspension of **6** (0.50 g, 1.80 mmol) in acetonitrile (10 mL) were added 37% aqueous formaldehyde (0.54 g, 18.00 mmol, 10 equiv.) and the mixture was heated under reflux for 1 h. After cooling, sodium cyanoborohydride (NaBH₃CN) (0.34 g, 5.4 mmol, 3.0 equiv.) and the mixture was stirred at reflux temperature for 2 h. After cooling, the reaction mixture was evaporated to dryness and the residue was partitioned between chloroform (3 × 20 mL) and water (20 mL). The combined organic extracts were dried (Na₂SO₄), filtered and evaporated to dryness, and the residue was poured onto SiO₂ column.

Elution, in gradient, with methanol (0–10%) and chloroform, as eluent, afforded **8** (0.40 g, 74%), m.p. 139–143°C. ¹H NMR (DMSO-*d*₆): δ 7.48 (m, 2H, Ar-H); 7.32 (m, 3H, Ar-H); 3.38 (m, 2H, CH₂-1'); 3.21 (s, 6H, NMe₂); 1.48 (m, 2H, CH₂-2'); 0.83 (t, 3H, *J* = 7.0 Hz, CH₃). ¹³C NMR (DMSO-*d*₆): δ 161.6 (C-4); 151.1 (C-2); 135.6; 129.5, 129.0 (Ar-C); 126.8 (C-6); 125.8 (C-6, ArC); 106.9 (C-5); 48.0 (C-1'); 40.1 (NMe₂); 21.7 (C-2'); 11.1 (C-3'). Anal. calcd. for C₁₅H₁₉N₃O₂S (305.4): C, 58.99; H, 6.27; N, 13.76. Found: C, 58.73; H, 6.16; N, 13.51. MS: *m/z* (FAB) 328 (M+Na)⁺.

(E)-5-(3,4-Dimethoxybenzylideneamino)-6-phenylsulfanyl-1-propyl-1H-pyrimidin-2,4-dione (9)

A solution of **7** (0.50 g, 1.80 mmol) in EtOH (20 mL) containing 2,4-dimethoxybenzaldehyde (0.33 g, 2.00 mmol) was heated under reflux for 3 h. After cooling, the crystals were filtered and washed with cold EtOH to give **9** (0.59 g, 77%), m.p. 155–158°C. ¹H NMR (DMSO-*d*₆): δ 7.63–7.25 (m, 9H, Ar-H + CH=N); 3.86, 3.82 (2xs, 6H, 2xOMe); 3.67 (m, 2H, CH₂-1'); 1.42 (m, 2H, CH₂-2'); 0.81 (t, 3H, *J* = 7.0 Hz, CH₃). ¹³C NMR (DMSO-*d*₆): δ 160.3 (CH=N); 157.0 (C-4); 148.1 (C-2, C-6); 128.3 (Ar-C-OMe), 127.7, 127.6, 125.4, 123.9 (Ar-C); 90.8 (C-5), 60.0 (OMe);

45.7 (C-1'); 21.2 (C-2'); 11.3 (C-3'). Anal. calc. for $C_{22}H_{23}N_3O_4S$ (425.5): C, 62.10; H, 5.45; N, 9.88. Found: C, 61.89; H, 5.39; N, 9.71. MS: m/z (FAB) 426 ($M+H$)⁺.

6-Chloro-1,3-dimethyl-5-nitro-1H-pyrimidin-2,4-dione (11)

Compound **11** was prepared by Pfeleiderer et al.²⁹ and Clark et al.³⁰

6-Arylsulfanyl-1,3-dimethyl-5-nitro-1H-pyrimidin-2,4-diones (12–15)—General Procedure

A solution of chloro compound **11** (1.71 g, 9.37 mmol) in DMF (20 mL) and arylmercaptan (18.74 mmol) was heated at 120°C (DMF) for 12 h. After cooling, the solution was evaporated to dryness and the residue was recrystallized from ethanol or ethanol/methanol to give the desired products **12–15**.

1,3-Dimethyl-5-nitro-6-phenylsulfanyl-1H-pyrimidin-2,4-dione (12)

From sodium phenylthiolate (2.47 g). Yield: 1.89 g (69%), m.p. 308–311°C. ¹H NMR (DMSO-*d*₆): δ 7.58 (m, 2H, Ar-H); 7.31 (m, 2H, Ar-H); 3.07, 3.00 (2s, 6H, 2xCH₃). ¹³C NMR (DMSO-*d*₆): δ 159.4 (C-4); 156.2 (C-2); 148.1 (C-6); 130.8, 128.3, 127.5, 125.4 (Ar-C); 105.5 (C-5); 27.0, 26.7 (Me). Anal. Calc. for $C_{12}H_{11}N_3O_4S$ (293.3): C, 49.14; H, 3.78; N, 14.33. Found: C, 48.89; H, 3.70; N, 14.01. MS: m/z (FAB) 328 ($M+Na$)⁺.

1,3-Dimethyl-5-nitro-6-(pyridin-4-ylthio)-1H-pyrimidin-2,4-dione (13)

From 4-pyridinethiol (2.08 g). Yield: 1.43 g (52%), m.p. 211–214 dec.°C. ¹H NMR (DMSO-*d*₆): δ 8.60 (d, 2H, *J* = 7.5 Hz, Ar-Hc,e); 7.61 (d, 2H, *J* = 7.5 Hz, Ar-Hb,f); 3.11, 3.09 (2s, 6H, 2xCH₃). ¹³C NMR (DMSO-*d*₆): δ 162.2 (C-4); 157.1 (C-2); 148.6 (C-6); 129.8, 128.7, 128.9, 126.7 (Ar-C); 108.1 (C-5); 27.5, 27.0 (Me). Anal. calcd. for $C_{11}H_{10}N_4O_4S$ (294.29): C, 44.89; H, 3.43; N, 19.04. Found: C, 44.65; H, 3.33; N, 18.87. MS: m/z (FAB) 295 ($M+H$)⁺.

1,3-Dimethyl-5-nitro-6-(pyridin-N-oxide-4-ylsulfanyl)-1H-pyrimidin-2,4-dione (14)

From 4-(*N*-oxidepyridine)thiol (2.38 g). Yield: 1.77 g (61%), m.p. 200–202 dec.°C. ¹H NMR (DMSO-*d*₆): δ 8.08 (d, 2H, *J* = 8.1 Hz, Ar-Hc,e); 7.37 (d, 2H, *J* = 8.1 Hz, Ar-Hb,f); 3.09, 3.01 (2s, 6H, 2xCH₃). ¹³C NMR (DMSO-*d*₆): δ 164.2 (C-4); 157.9 (C-2); 150.1 (C-6); 136.2 (Ar-Cc,e), 131.1 (Ar-Cb,f); 112.9 (C-5); 27.7, 27.2 (Me). Anal. calcd. for $C_{11}H_{10}N_4O_5S$

(310.29): C, 42.58; H, 3.25; N, 18.06. Found: C, 42.32; H, 3.09; N, 17.89. MS: m/z (FAB) 311 ($M+H$)⁺.

6-(4-Chlorophenylsulfanyl)-1,3-dimethyl-5-nitro-1H-pyrimidin-2,4-dione (15)

From 4-chlorophenylmercaptan (2.69 g). Yield: 1.62 (53%), m.p. 132–137°C. ¹H NMR (DMSO-*d*₆): δ 8.08 (d, 2H, $J = 8.1$ Hz, Ar-Hc,e); 7.37 (d, 2H, $J = 8.1$ Hz, Ar-Hb,f); 3.09, 3.01 (2s, 6H, 2xCH₃). ¹³C NMR (DMSO-*d*₆): δ 157.2 (C-4); 151.0 (C-2); 145.0 (C-6); 131.0, 129.5 (Ar-C), 111.9 (C-5); 27.0, 26.9 (Me). Anal. calcd. for C₁₂H₁₀ClN₃O₄S (327.74): C, 43.98; H, 3.08; N, 12.82. Found: C, 43.69; H, 2.92; N, 12.61. MS: m/z (FAB) 350 ($M + Na$)⁺.

2-Amino-5-nitro-6-phenylsulfanyl-1H-pyrimidin-4-one (17)

This compound was prepared from **16** (0.65 g, 2.96 mmol) according to the procedure of preparation of **3**. Yield: 0.51 g (65%), m.p. 233–235°C. ¹H NMR (DMSO-*d*₆): δ 11.27 (br s., 2H, NH₂); 7.40–7.34 (m, 5H, Ar-H). ¹³C NMR (DMSO-*d*₆): δ 188.2 (C-5); 173.2 (C-7); 144.6 (C-9); 139.8 (C-2); 135.0, 133.1, 129.3, 129.1, 128.7, 127.2, 125.4 (Ar-C), 124.3 (C-3); 115.1 (C-6). Anal. calcd. for C₁₀H₈N₄O₃S (264.26): C, 45.45; H, 3.05; N, 21.20. Found: C, 45.19; H, 3.98; N, 20.98. MS: m/z (FAB) 328 ($M+Na$)⁺.

2-Amino-2-phenyl-7-phenylsulfanyl-imidazo[1,2- α]pyrimidin-5-one (18)

To a solution of **17** (0.30 g, 1.13 mmol) in anhydrous DMF (10 mL) containing NaH (0.06 g, 2.5 mmol) was added α -bromoacetophenone (0.32 g, 1.6 mmol). The reaction mixture was stirred at 23°C for 5 h, followed by the addition of NH₄OH solution (7 mL) at 23°C to give, after chromatography, **18** (0.21 g, 51%), m.p. 192–195°C. ¹H NMR (DMSO-*d*₆): δ 7.45–7.41 (m, 5H, C₈–Ar-H); 7.26–7.18 (m, 5H, S–Ar-H); 7.15 (s, 1H, H-3). ¹³C NMR (DMSO-*d*₆): δ 188.2 (C-4); 173.2 (C-6); 144.6 (C-2); 139.8 (C-8); 135.0, 133.1, 129.3, 129.1, 128.7, 127.2, 125.4 (Ar-C), 124.3 (C-7); 115.1 (C-5). Anal. calcd. for C₁₈H₁₂N₄O₃S (364.38): C, 59.33; H, 3.32; N, 15.38. Found: C, 58.92; H, 3.19; N, 15.09. MS: m/z (FAB) 365 ($M+H$)⁺.

ACKNOWLEDGMENTS

We thank Professor E. De Clercq and Professor C. Pannecouque of Rega Institute of Medical Research, Katholieke Universiteit, Leuven, Belgium, for the anti-HIV screening. Miss Friemel of Konstanz

University (Germany) is gratefully acknowledged for the 2 D NMR experiments.

REFERENCES

- [1] E. De Clercq, *Med. Chem. Res.*, **13**, 439 (2004).
- [2] E. De Clercq, *Chem. Biodiver.*, **1**, 44 (2004).
- [3] G. Barbaro, A. Scozzafava, A. Mastrolorenzo, and C.T. Supuran, *Curr. Pharm. Design*, **11**, 1805 (2005).
- [4] R. A. Koup, V. J. Merluzzi, K. D. Hargrave, J. Adams, K. Grozinger, R. J. Eckner, and J. L. Sullivan, *J. Infect. Dis.*, **163**, 966 (1991).
- [5] D. L. Romero, R. A. Morge, C. Biles, T. N. Berrios-Pena, P. D. May, J. P. Palmer, P. M. Johnson, H. W. Smith, M. Busso, C. -K. Tan, R. L. Voorman, F. Reusser, I. W. Althaus, K. M. Downey, A. G. So, L. Resnick, W. G. Tarpley, and P. A. Aristoff, *J. Med. Chem.*, **37**, 999 (1994).
- [6] D. L. Romero, R. A. Olmsted, T. J. Poel, R. A. Morge, C. Biles, B. J. Keiser, L. A. Kopta, J. M. Friis, J. D. Hosley, K. J. Stefanski, D. G. Wishka, D. B. Evans, J. Morris, R. G. Stehle, S. K. Sharma, Y. Yagi, R. L. Voorman, W. J. Adams, W. G. Tarpley, and R. C. Thomas, *J. Med. Chem.*, **39**, 3769 (1996).
- [7] S. D. Young, S. F. Britcher, L. O. Tran, L. S. Payne, W. C. Lumma, T. A. Lyle, J. R. Huff, P. S. Anderson, D. B. Olsen, S. S. Carroll, D. J. Pettibone, J. A. Obrien, R. G. Ball, S. K. Balani, J. H. Lin, I. W. Chen, W. A. Schleif, V. V. Sardana, W. J. Long, V. W. Byrnes, and E. A. Emimi, *Antimicrob. Agents Chemother.*, **39**, 2602 (1995).
- [8] M. A. Wainberg, J. P. Sawyer, J. S. Montaner, R. L. Murphy, D. R. Kuritzkes, and F. Raffi, *Antiviral Therapy*, **10**, 13 (2005).
- [9] T. Imamichi, *Curr. Pharma. Design*, **10**, 4039 (2004).
- [10] R. Benhida, A.-M. Aubertin, D. S. Grierson, and D. S. Monneret, *Tetrahedron Lett.*, **37**, 1031 (1996).
- [11] S. Yousif and H. Yamamoto, *Phosphorus, Sulfur, Silicon Relat. Elem.*, **140**, 227 (1998).
- [12] T. Miyasaka, H. Tanaka, M. Baba, H. Hayakawa, R. T. Walker, J. Balzarini, and E. De Clercq, *J. Med. Chem.*, **32**, 2507 (1989).
- [13] Y. A. Al-Soud and N. A. Al-Masoudi, *Arch. Pharm. Med. Chem.*, **332**, 143 (1999).
- [14] Y. A. Al-Soud, H. H. Al-Sa'doni, H. A. S. Amajaour, M. S. Mubarak, N. A. Al-Masoudi, and I. H. Jaber, *Z. Naturforschungs*, **63b**, 83 (2008).
- [15] N. A. Al-Masoudi, Y. A. Al-Soud, A. Kalogerakis, E. De Clercq, and C. Pannecoque, *Chem. Biodiver.*, **3**, 515 (2006).
- [16] Y. A. Al-Soud, H. Al-Sa'doni, H. A. S. Amajaour, and N. A. Al-Masoudi, *Z. Naturforschungs*, **62b**, 523 (2007).
- [17] Y. A. Al-Soud, N. A. Al-Masoudi, E. De Clercq, and C. Pannecoque, *Heteroatom Chem.*, **4**, 333 (2007).
- [18] N. A. Al-Masoudi, Y. A. Al-Soud, E. De Clercq, and C. Pannecoque, *Antiviral Chem. & Chemother.*, **18**, 191 (2007).
- [19] Y. A. Al-Soud, N. A. Al-Masoudi, H. Gh. Hassan, E. De Clercq, and C. Pannecoque, *Acta Pharm.*, **57**, 379 (2007).
- [20] C. Wood, *Proc. Chem. Soc. London*, 387 (1959); *J. Chem. Soc.*, **4768**, 4773 (1960).
- [21] C. Temple, C. L. Kussner, and J. A. Montgomery, *J. Org. Chem.*, **33**, 2086 (1968).
- [22] V. J. Ram, W. R. Knappe, and W. Pfeleiderer, *Leibigs Ann. Chem.*, **4**, 762 (1982).
- [23] S. S. Al-Hassan, R. J. Kulick, D. B. Livingstone, C. J. Suckling, H. C. S. Wood, R. Wigglesworth, and R. Ferone, *J. Chem. Soc. Perkin Trans.*, **1**, 2645 (1980).

- [24] V. A. Makarov, A. L. Sedov, M. P. Nemeryuk, and T. S. Safonov, review, *Pharm. Chem. J.*, **27**, 245 (1993).
- [25] K. Eger, E. M. Kluender, and M. Schmidt, *J. Med. Chem.*, **37**, 3057 (1994).
- [26] K.-Y. Zee-Cheng and C. C. Cheng, *J. Med. Chem.*, **11**, 1107 (1968).
- [27] F. Wormstaedt, U. Brinckmann, M. Guetschow, and K. Kurt, *J. Heterocycl. Chem.*, **37**, 1187 (2000).
- [28] M. P. Nemeryuk, A. L. Sedov, V. A. Makarov, N. P. Solov'eva and T. S. Safonova, *Chem. Heterocycl. Comp.*, **27**, 804 (1991).
- [29] W. Pfeleiderer, J. E. Bühler, *Chem. Ber.*, **99**, 2997 (1966).
- [30] J. Clark and I. W. Sonthon, *J. Chem. Soc. Perkin Trans. 1*, 1814 (1978).
- [31] T. D. Gross, Y.-F. Zhu, J. Saunders, K. M. Wilcoxon, Y. Gao, P. J. Connors, Jr., Z. Guo, R. S. Struthers, G. J. Reinhart, and C. Chen, *Boorrg. Med. Chem. Lett.* **12**, 2185 (2002), and references therein cited.
- [32] W. Willker, D. Leibfritz, R. Kerssebaum, and W. Bermel, *Magn. Res. Chem.*, **31**, 287 (1993).
- [33] E. De Clercq, *Antiviral Res.*, **12**, 1 (1989).
- [34] M. Baba, E. De Clercq, S. Iida, H. Tanaka, I. Nitta, M. Ubasawa, H. Takashima, K. Sekiya, K. Umezu, H. Nakashima, S. Shigeta, R. T. Walker, and T. Miyasaka, *Antimicrob. Agents Chemother.*, **34**, 2358 (1990).
- [35] T. Fujiwara, A. Sato, M. El-Farrash, S. Miki, K. Kabe, Y. Isaka, M. Kodama, Y. M. Wu, L. B. Chen, H. Harada, H. Sugimoto, M. Hatanaka, and Y. Hinuma, *Antimicrob. Agents Chemother.* **42**, 13401 (1998).